Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2019-09-15 Regulatory Filings
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Nya interimsdata i RRMM-patienter med metastaserad cancer (EMD) från den pivotala fas 2-studien HORIZON presenteras på International Myeloma Workshop
Regulatory Filings Classification · 1% confidence The document is a press release from Oncopeptides AB, dated September 15, 2019, written in Swedish. The content announces that updated efficacy and safety data from the pivotal Phase 2 HORIZON study (OP-106) regarding melflufen in RRMM patients with EMD will be presented at the 17th International Myeloma Workshop (IMW). It details key interim results (ORR, OS) and announces a subsequent conference call for investors/analysts to discuss these findings. This structure—announcing the presentation of clinical trial data and scheduling a follow-up call—is characteristic of an Earnings Release (ER) or a general announcement related to clinical/financial updates. Since it is primarily focused on releasing key clinical trial results (which often accompany or precede formal earnings reports) and is structured as a formal announcement of data presentation, it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical financial/operational results, or potentially a Regulatory Filing (RNS) if it were purely regulatory. Given the focus on presenting study data and scheduling a call to review results, ER is the most appropriate fit among the specific options, as it communicates key operational/clinical performance highlights. It is not a full report (10-K, IR), a presentation (IP), or just a notice of a report publication (RPA).
2019-09-15 Swedish
New Interim Data in RRMM Patients with Extramedullary Disease from the Pivotal Phase 2 Horizon-study presented at International Myeloma Workshop
Regulatory Filings Classification · 1% confidence The document is a press release dated September 15, 2019, announcing updated interim efficacy and safety data from the Phase 2 HORIZON study presented at the International Myeloma Workshop (IMW). It details clinical results (ORR, median survival) and includes commentary from a key investigator, followed by details of an upcoming conference call to review the data. This structure—announcing clinical data presentation and scheduling a call to discuss it—is characteristic of an Earnings Release (ER) or a general announcement related to financial/operational performance updates. Since it is a press release focused on clinical trial results and future investor communication (conference call), it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical results or significant operational milestones, even if not strictly quarterly financials. It is not a full report (10-K, IR), a presentation (IP), or just a call transcript (CT).
2019-09-15 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive 'Delårsrapport Q2 2019' (Interim Report Q2 2019) for Oncopeptides AB. It contains detailed financial statements, a management commentary (VD kommenterar), summaries of clinical trials, and operational updates for the period of April to June 2019. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis. Q2 2019
2019-08-28 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT Q2 2019' and contains comprehensive financial data, including a financial overview, income statements, and management commentary for the period April 1 to June 30, 2019. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q2 2019
2019-08-28 English
Oncopeptides appoints Klaas Bakker as new Chief Medical Officer
Board/Management Information Classification · 1% confidence The document is a press release dated August 20, 2019, announcing a specific change in senior personnel: the appointment of Klaas Bakker as the new Chief Medical Officer (CMO) and the transition of the previous CMO, Johan Harmenberg. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2019-08-20 English
Oncopeptides utser Klaas Bakker som ny Chief Medical Officer
Board/Management Information Classification · 1% confidence The document is a press release dated August 20, 2019, announcing a change in senior management: the appointment of Klaas Bakker as the new Chief Medical Officer (CMO) and the retirement of the previous CMO. This directly corresponds to the definition of Board/Management Information.
2019-08-20 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.